Genfit updates on research pipeline
French biotech firm Genfit (Euronext: GNFT) on Friday outlined important developments in its research pipeline
Among these was regarding its investigational treatment elafibranor, which is now partnered with fellow French drugmaker Ipsen (Euronext: IPN), noting that top-line Phase III results for the ELATIVE study in primary biliary cholangitis (PBC) are now expected to be announced towards the end of second-quarter 2023.
Meantime, Genfit noted, Phase II results showed a statistically-significant improvement on both the primary and composite biochemical evaluation criteria, the latter now being the primary endpoint of the pivotal Phase III trial to support accelerated approval. In addition, the results showed a positive trend on the improvement of pruritus, while preserving a favorable safety and tolerability profile. These positive conclusions were published in the Journal of Hepatology in 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze